Inflammatory Skin Diseases and CKD Risk: What’s the Link?

Sarfaroj Khan 


March 23, 2021


Why this matters

  • Findings warrant further research to elucidate the nature and temporal direction of this link, to account for other potential confounders, and explore whether targeted screening for CKD in people with inflammatory skin diseases is justified.

Study design

  • Researchers conducted 2 complementary analyses (case-control and cohort study) using data from the UK Clinical Practice Research Datalink.

  • 56,602 patients with CKD stages 3-5 were matched with 268,305 control participants in the case-control study; 335,827 patients with diabetes were included in the cohort study.

  • Funding: None.

Key results

  • Patients with CKD3-5 vs those without were more likely to have a history of (adjusted OR [aOR]; 99% CI):

    • atopic eczema (1.14; 1.11-1.17);

    • psoriasis (1.13; 1.08-1.19); and

    • hidradenitis suppurativa (1.49; 1.19-1.85).

  • CKD3-5 was associated with lower prevalence of rosacea (aOR, 0.92; 95% CI, 0.87-0.97).

  • Results remained similar after adjusting for hypertension and cardiovascular disease (aOR; 99% CI):

    • atopic eczema (1.10; 1.07-1.13);

    • psoriasis (1.12; 1.07-1.17); and

    • hidradenitis suppurativa (1.45; 1.16-1.82).

  • Patients with atopic eczema and psoriasis were more likely to have CKD3-5, irrespective of atopic eczema and psoriasis severity. The association was stronger in patients with more severe skin disease (Ptrend<.0001).

  • No association was seen between CKD3-5 incidence and atopic eczema and psoriasis in people with diabetes.


  • Risk of misclassification.

  • Risk of potential confounders.


Schonmann Y, Mansfield KE, Mulick A, Roberts A, Smeeth L, Langan SM, Nitsch D. Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease - Population-Based Case-control and Cohort analyses. Br J Dermatol. 2021 Mar 17 [Epub ahead of print]. doi: 10.1111/bjd.20067. PMID: 33730366.  View abstract  

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.